Beta-1A
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2282 publications
Natalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model.
Journal: Health technology assessment (Winchester, England)
Published: August 11, 2026
Dynamics of Myelin-Specific T-Cell Repertoires Mirror Disease Activity and Central Nervous System Trafficking in Multiple Sclerosis.
Journal: International journal of molecular sciences
Published: June 17, 2026
Effect of inhaled interferon-β1a on SARS-CoV-2 diversity and evolution.
Journal: Microbiology spectrum
Published: May 18, 2026
Posterior Segment Involvement in Subacute Sclerosing Panencephalitis: Clinical Features and Outcomes.
Journal: Ocular immunology and inflammation
Published: April 18, 2026
Clinical, demographic, and pharmacological predictors of medication adherence to disease-modifying therapies in multiple sclerosis: a multidimensional analysis of merged survey and claims data.
Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: March 10, 2026
Immunotherapy-Mediated Modulation of the Gut Microbiota in Multiple Sclerosis: The Effects of High-Efficacy (Cladribine) and Moderate-Efficacy (Interferon Beta-1a) Treatments.
Journal: International journal of molecular sciences
Published: March 07, 2026
Urinary tract infections, urosepsis, and multiple sclerosis disease modifying therapies: a disproportionality analysis of the FDA Adverse Event Reporting System.
Journal: Multiple sclerosis and related disorders
Published: February 03, 2026
Identification of Drug Repurposing Opportunities of Immunomodulatory Drugs for Inflammatory Bowel Disease Through Inverse Pharmacovigilance Signal Detection in the FAERS Database.
Journal: Journal of clinical medicine
Published: February 01, 2026
LncRNA AFAP1-AS1 mediates therapy-dependent expression of CCL5, CXCL10 and MMP9 in multiple sclerosis.
Journal: Biochemistry and biophysics reports
Published: January 19, 2026
Multiple sclerosis patients under treatment with interferon β1-a or ocrelizumab exhibit different T and B cell responses to SARS-CoV-2 vaccine.
Journal: Frontiers in immunology
Published: December 22, 2025
The comparative efficacy of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis: Updated meta-regression estimates by patient subgroup.
Journal: Multiple sclerosis and related disorders
Published: December 20, 2025
Updated systematic literature review and network meta-analysis of cladribine tablets versus currently approved disease-modifying treatments for active relapsing-remitting multiple sclerosis.
Journal: Multiple sclerosis and related disorders
Published: December 19, 2025
Last Updated: 09/26/2026